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Abstract: Purpose: Classical type of lobular neoplasia (LN) encompassing both atypical lobular hyper-
plasia and classical lobular carcinoma in situ of the breast is a lesion with uncertain malignant potential
and has been the topic of several studies with conflicting outcome results. The aim of our study was to
clarify outcome-relevant factors and treatment options of classical LN. Methods: We performed a patho-
logical re-evaluation of the preoperative biopsy specimens and a retrospective clinical and radiological
data analysis of 160 patients with LN from the Breast Center Zurich. Open surgery was performed in 65
patients, vacuum-assisted biopsy (VAB) in 79 patients, and surveillance after breast core needle biopsy
(CNB) in 16 patients. Results: The upgrade rate into ductal carcinoma in situ/invasive cancer was the
highest in case of imaging/histology discordance (40%). If the number of foci in the biopsy specimen
was ฀3, the upgrade rate in the consecutive surgical specimens was increased (p = 0.01). The association
of classical LN with histological microcalcification correlated with shortened disease-free survival (p <
0.01), whereas other factors showed no impact on follow-up. Conclusions: Surveillance or subsequent
VAB after CNB of LN is sufficient in most cases. Careful consideration of individual radiological and
histological factors is required to identify patients with a high risk of upgrade into malignancy. In those
cases, surgical excision is indicated.
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Abstract
Purpose: Classical type of lobular neoplasia (LN) encompass-
ing both atypical lobular hyperplasia and classical lobular 
carcinoma in situ of the breast is a lesion with uncertain ma-
lignant potential and has been the topic of several studies 
with conflicting outcome results. The aim of our study was 
to clarify outcome-relevant factors and treatment options of 
classical LN. Methods: We performed a pathological re-eval-
uation of the preoperative biopsy specimens and a retro-
spective clinical and radiological data analysis of 160 pa-
tients with LN from the Breast Center Zurich. Open surgery 
was performed in 65 patients, vacuum-assisted biopsy (VAB) 
in 79 patients, and surveillance after breast core needle bi-
opsy (CNB) in 16 patients. Results: The upgrade rate into 
ductal carcinoma in situ/invasive cancer was the highest in 
case of imaging/histology discordance (40%). If the number 
of foci in the biopsy specimen was ≥3, the upgrade rate in 
the consecutive surgical specimens was increased (p = 0.01). 
The association of classical LN with histological microcalcifi-
cation correlated with shortened disease-free survival (p < 
0.01), whereas other factors showed no impact on follow-up. 
Conclusions: Surveillance or subsequent VAB after CNB of 
LN is sufficient in most cases. Careful consideration of indi-
vidual radiological and histological factors is required to 
identify patients with a high risk of upgrade into malignancy. 
In those cases, surgical excision is indicated.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Early detection of breast cancer by clinical imaging 
has been established in many countries [1]. Approxi-
mately 5–15% of screen-detected abnormalities include 
lesions with uncertain malignant potential (B3), of 
which classical lobular neoplasia (LN), encompassing 
both atypical lobular hyperplasia and classical lobular 
carcinoma in situ, is represented in 10–20% [2–4]. Since 
the classical type of LN was first described, its diagnosis 
and treatment recommendations have undergone some 
fundamental changes [5]. Until today, conflicting data 
can put patient, radiologist, and surgeon in the uncom-
fortable position of having no strong management rec-
ommendation [6]. Open surgical excision of LN has 
This is an Open Access article licensed under the Creative Commons 
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been the standard over decades [7]. Within the last years, 
there has been a trend towards minimally invasive man-
agement with vacuum-assisted biopsy (VAB) and fre-
quent surveillance [8]. However, crucial points remain 
unclear. First, the diagnosis of LN has been considered 
“incidental,” as there seem to be no typical patterns for 
this lesion. On the other hand, microcalcifications on 
mammogram are described as concordant and “typical” 
findings of LN [6]. Second, upgrade rates into ductal 
carcinoma in situ (DCIS) or invasive cancer show a tre-
mendous variety from 4 to 44% within the current lit-
erature [9–12], which is also true for the follow-up out-
come. The risk of developing breast cancer is increased 
up to four times [9, 13]. Finally, discordance of imaging 
findings and histopathological diagnosis of LN was con-
sidered in a limited number of studies [12, 14–17]. It 
remains unclear whether there is an alternative option 
to open surgery in case of discordance. Obvious differ-
ences in designs in the cited studies and the expected 
connection between clinical imaging, diagnostic meth-
od, histopathological characters, and outcome of LN 
have not been delivered for an adequate number of pa-
tients so far.
The purpose of the study was to explore outcome-rel-
evant imaging and histological factors to facilitate the de-
cision-making process for patients with the diagnosis of 
LN in biopsy specimen. Endpoints were upgrade rate into 
DCIS/invasive cancer and disease-free follow-up. We as-
sessed imaging features, histopathological features, con-
cordance of these findings, and further treatment.
Methods
Case Selection
The data of 201 patients with biopsy-detected pure classical LN 
were derived from the institutional database of the Breast Center 
Zurich between 2008 and 2018. Medical records were reviewed for 
patients’ personal data, diagnosis, and treatment. After a careful 
histopathological review of all paraffin-embedded breast biopsy 
specimens by an advanced fellow resident (A.-K.R.) and a breast 
pathologist (Z.V.), 41 patients were excluded from the analysis due 
to the coexistence of invasive carcinoma or DCIS in the biopsy 
specimens (n = 6), coexistence of other B3 lesions (n = 32), or the 
presence of pleomorphic LN (n = 3), which corresponds to a B5 
lesion [18].
Clinical Imaging and Biopsy Technique
All patients received clinical breast imaging with standardized 
mammogram and ultrasound. Additional MRI was performed in 
37 cases. Lesions were evaluated by trained breast radiologists and 
recorded by their type, BI-RADS® classification, and size (if avail-
able) [19]. In sonographically evident lesions, ultrasound-guided 
core needle biopsy (CNB) was performed with a 14-G needle (Tru-
Cut®) and a minimum of three cores per lesion. In mammograph-
ically evident but sonographically occult lesions, stereotactic VAB 
was performed with an 11-G or 7-G needle and a minimum of six 
cores per lesion.
Histopathological Review
The formalin-fixed, paraffin-embedded biopsy specimens were 
processed according to the standardized protocols of the Depart-
ment of Pathology and Molecular Pathology, University Hospital 
Zurich, Switzerland. The following points were considered in the 
analysis: (1) histological diagnosis of classical LN encompassing 
both lobular hyperplasia and classical lobular carcinoma in situ, 
(2) the presence of associated calcification, and (3) the number of 
LN foci in the biopsy cylinders. Additional immunohistochemis-
try reactions (such as E-cadherin loss and in most cases also cyto-
plasmic catenin p120 stains) further confirmed lobular differen-
tiation and excluded ductal proliferation such as usual ductal hy-
perplasia or adenosis.
Treatment Decision
Discordance between radiological findings and histology of LN 
was defined as as BI-RADS® 5 (>95% malignancy) classification in 
the mammogram and/or ultrasound and/or MRI, or BI-RADS® 4 
(20–40% malignancy) lesions, in which the histopathology of LN 
or coincidental benign findings did not correspond with the clini-
cal imaging. All cases of discordant findings and most cases with 
concordant findings were discussed in the multidisciplinary pre-
operative tumor board of our breast center, which gave a consent 
recommendation for further treatment, including surgical exci-
sion, VAB (if the initial diagnosis was set by CNB), or surveillance.
Statistics
For the descriptive analysis, mean (standard deviation) or me-
dian were used for continuous variables, and number and percent-
age were used for categorical variables. Disease-free survival was 
visualized with Kaplan-Meier plots of survival probability. χ2 tests 
were performed (p value for significance <0.05). All analyses were 
performed in the R programing language.
Results
Overall, 160 patients with classical LN were included 
in the study (Table 1). The mean age was 56.9 years; the 
main reason for initial presentation at the breast center 
was screening or follow-up (n = 77 [48.1%] and n = 45 
[28.1%], respectively).
Histopathological Review
Most specimens contained one focus of LN (119 of 160 
cases, 74.4%) (Fig. 1). With a higher number of foci, the 
risk of upgrading also increased (p = 0.011) (Table 1). Due 
to the larger sample volume of biopsy specimens, multiple 
LN foci were more often observed in VAB than in CNB 
(10 of 53 [18.9%] vs. 13 of 107 [12.1%]). Histopathological 
association of classical LN with microcalcification was ob-
served in 11.9% (19 of 160) (Table 1; Fig. 2), which how-
ever showed no significant association with upgrade, but 
showed a significant correlation with disease-free survival 
in the follow-up outcome (p = 0.001) (Fig. 3).
Clinical Imaging and Discordant Findings
The average lesion size was 13.6 mm in mammogram 
and 13.3 mm in ultrasound. Microcalcification and mass 
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Table 1. Clinical data, imaging, and histopathology of patients with LN who had an upgrade/no upgrade in final histology
Overall Upgrade in 
final histology
No upgrade in 
final histology
p value
n (%) 160 (100%) 17 (10.6%) 143 (89.4%)
Mean age, years (SD) 56.9 (11.7) 60.1 (11.7) 56.5 (11.7) 0.248
Risk of hereditary breast cancer 0.530
Yes 34 (21.2%) 2 (5.9%) 32 (94.1%)
No/unknown 126 (78.8%) 15 (11.9%) 111 (88.1%)
Previous contralateral breast cancer 0.745
Yes 31 (19.4%) 4 (12.9%) 27 (87.1%)
No 129 (80.6%) 13 (10.1%) 116 (89.9%)
Diagnostic method 0.088
Tru-Cut® biopsy 107 (66.9%) 15 (14.0%) 92 (86.0%)
VAB 53 (33.1%) 2 (3.8%) 51 (96.2%)
Ultrasound classification according to BI-RADS® 0.015
BI-RADS® 1 6 (3.8%) 0 6 (100%)
BI-RADS® 2 37 (23.6%) 2 (5.4%) 35 (94.6%)
BI-RADS® 3 73 (46.5%) 7 (9.6%) 66 (90.4%)
BI-RADS® 4 37 (23.6%) 5 (13.5%) 32 (86.5%)
BI-RADS® 5 4 (2.6%) 3 (75.0%) 1 (25.0%)
BI-RADS® 0 3 (1.9%) 1 (33.3%) 2 (66.6%)
Type of ultrasound lesion 0.998
Mass 94 (76.4%) 11 (11.7%) 83 (88.3%)
Microcalcification 2 (1.6%) 0 2 (100%)
Architectural distortion 19 (15.4%) 2 (10.5%) 17 (89.5%)
Cyst 8 (6.5%) 1 (12.5%) 7 (87.5%)
Unknown 37 3 (8.1%) 34 (91.9%)
Breast density 0.808
ACR a 0 0 0
ACR b 54 (34.4%) 7 (13.0%) 47 (87.0%)
ACR c 86 (54.8%) 9 (10.5%) 77 (89.5%)
ACR d 17 (10.8%) 1 (5.9%) 16 (94.1%)
Mammogram classification according to BI-RADS® 0.047
BI-RADS® 1 1 (0.7%) 0 1 (100%)
BI-RADS® 2 58 (37.7%) 5 (8.6%) 53 (91.4%)
BI-RADS® 3 36 (23.4%) 6 (16.7%) 30 (83.3%)
BI-RADS® 4 52 (33.8%) 3 (5.8%) 49 (94.2%)
BI-RADS® 5 7 (4.6%) 3 (42.9%) 4 (57.1%)
BI-RADS® 0 6 (3.8%) 0 6 (100%)
Type of mammographic lesion 0.770
Mass 39 (24.4%) 3 (7.7%) 36 (92.3%)
Microcalcification 62 (38.8%) 7 (11.3%) 55 (88.7%)
Architectural distortion 13 (8.1%) 3 (23.1%) 10 (76.9%)
Cyst 19 (11.9%) 4 (21.1%) 15 (78.9%)
Unknown 27 (16.9%) 5 (18.5%) 22 (81.5%)
Discordance <0.001
Yes 20 (12.5%) 8 (40.0%) 12 (60.0%)
No 140 (87.5%) 9 (6.4%) 131 (93.6%)
Number of histological LN foci in biopsy specimens 0.011
1 119 (74.4%) 9 (7.6%) 110 (92.4%)
2 18 (11.2%) 2 (11.1%) 16 (88.9%)
≥3 23 (14.4%) 6 (26.0%) 17 (73.9%)
LN associated with microcalcification in histopathology 
of biopsy specimen 0.123
Yes 19 (11.9%) 4 (21.1%) 15 (78.9%)
No 141 (88.1%) 13 (9.2%) 128 (90.8%)
ACR, American College of Radiology; LN, lobular neoplasia; VAB, vacuum-assisted biopsy.
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(n = 62 [38.8%] and n = 39 [24.4%], respectively) were the 
main lesion characteristics in mammogram; mass and ar-
chitectural distortion were the central findings in ultra-
sound (n = 94 [58.8%] and n = 19 [11.9%], respectively) 
(Table 1). Most of the patients underwent biopsy due to 
suspicious findings in mammogram (BI-RADS® 4 and 5 
in 59 cases, 36.9%) and/or ultrasound (BI-RADS® 4 and 
5 in 41 cases, 25.6%). In the remaining cases, biopsy was 
performed due to BI-RADS® 3 findings despite a low 
likelihood of malignancy (≤2%) [19, 20]. Additional MRI 
was performed in 37 cases (23.1%); a BI-RADS 4 and 5 
classification was given in 19 cases (51.4%). Discordant 
findings of clinical imaging and histopathological diag-
nosis were reported in 20 cases (12.5%), most of which 
occurred after ultrasound-guided CNB had been per-
formed (n = 19).
Fig. 1. Histological appearance of classical 
LN. Vacuum-assisted biopsy demonstrates 
one focus of classical LN (type lobular car-
cinoma in situ, white arrow). There is an 
imaging relevant calcification in LN, shown 
also in inset (white arrow). The calcifica-
tion is in the middle of discohesive lobular 
cells filling the complete acini. All images 
hematoxylin & eosin stain. LN, lobular 
neoplasia.
Fig. 2. Histological appearance of classical 
LN. Vacuum-assisted biopsy showing four 
foci of classical LN (type atypical lobular 
hyperplasia, white arrows). There is only 
minimal calcification in LN. Imaging rele-
vant microcalcification is seen in columnar 
cell hyperplasia and flat epithelial atypia 
(back arrows) Upper Inset: large calcifica-
tion is seen in a duct in the adjacent vicin-
ity of columnar cell lesions. Lower inset: 
higher magnification of the atypical lobular 
hyperplasia shows discohesive lobular cells 
in a pagetoid spread. All images hematoxy-
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Further Diagnostic/Treatment and Upgrade Rate
The initial diagnosis of LN was given after CNB in 107 
cases and after VAB in 53 cases. Treatment decisions were 
made in the interdisciplinary tumor board of our breast 
center based on clinical, radiological, and pathological as-
pects. Out of 107 patients diagnosed by CNB, 53 (49.5%) 
received a subsequent surgical excision, 39 (36.4%) re-
ceived a secondary VAB, and 16 (14.9%) underwent sur-
veillance.
Patients with initial VAB (n = 53) received a surgical 
excision in 12 cases (22.6%). Surgical excision revealed 
DCIS/invasive cancer in 2 cases after VAB (16.7% of 53 
patients) and in 13 cases after CNB (24.5% of 107 pa-
tients). Secondary VAB led to an upgrade in 2 cases after 
CNB (1.9% of 107 patients). Patients without further in-
vasive diagnostic after initial LN diagnosis (16 [14.9%] of 
107 cases after CNB and 41 [77.4%] of 53 cases after VAB) 
underwent surveillance by annual follow-up with mam-
mogram and ultrasound. In most cases of discordant 
findings (n = 20), open surgery was performed (n = 14; 
70%), resulting in an upgrade in 6 cases (42.9%). Further 
sampling with VAB after initial CNB was performed in 2 
cases (10%; upgrade in both cases; 100%), and observa-
tion in 4 cases (20%; no event in follow-up). The risk of 
upgrade in the subsequent open surgery increased with 
the number of foci in the biopsy specimen (Table  1), 
whereas the association with microcalcification had no 
impact.
In most upgraded cases, we observed invasive lobular 
carcinoma (ILC) (n = 9; 52.9%) versus n = 6 (35.3%) of 
breast cancer of no special type (NST) and n = 2 (11.8%) 
of DCIS.
Follow-Up Outcome
Patients with upgrade into DCIS/invasive cancer (n = 
17; 10.6%) were excluded from the follow-up analysis. 
The median follow-up was 45 months, the median dis-
ease-free survival in the study population was 13.3 years. 
During follow-up, we observed events in 24 cases (16.8%), 
with recurrent B3 lesion in 7 cases. Malignancy occurred 
in 17 patients (11.9% of 143), in which the ipsilateral 
breast was affected in 11 patients, the contralateral breast 
in 4 patients, and bilateral in 2 cases. Patients with discor-
dant findings but without final histopathological upgrade 
did not differ in long-term outcome compared to patients 
with concordant findings. Long-term follow-up outcome 
was not improved in patients who underwent open sur-
gery with a DCIS/invasive cancer rate of 14% (7 of 50) 
versus 7.1% (4 of 56) in patients with surveillance and 
16.2% (6 of 37) in patients with VAB (either primary or 
secondary). If LN was histologically associated with cal-
cification, the disease-free survival was significantly low-




According to previous studies, we did not observe a 
typical imaging pattern of LN [21]. A histopathological 
association with microcalcification was detected in only 
19 of 61 cases that presented with microcalcification as 
the leading lesion in the mammogram. Most microcalci-
fications in mammogram or ultrasound were caused by 
coexisting benign lesions such as sclerosing adenosis, 
and the presence of microcalcification in clinical imaging 
was not associated with upgrade or poorer outcome. 
Considering that microcalcifications are the only poten-
tial radiological-pathological correlation that could be 
characteristic for LN, 88.1% of LN in our study group 
were incidental findings [21]. Likewise, mass as a leading 
lesion in ultrasound or mammogram in most cases was 
based on coincidental benign changes such as fibroade-
noma, pseudoangiomatous stromal hyperplasia, or fi-
brocystic changes and was regarded as being concordant 
to the imaging findings [22]. However, in a study group 
exclusively screened with mammogram, the number of 
histopathological association with microcalcification 
can be higher [6]. About 20% of the patients underwent 
Fig. 3. Disease-free follow-up of patients with LN pathologically 
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an additional MRI. Due to this limited number, a statisti-
cally relevant conclusion is not possible and was not the 
aim of the study. However, as MRI showed a lesion lead-
ing to the diagnosis of LN in 8 cases, we can emphasize 
the current practice of additional MRI in selected pa-
tients.
Radiological-Pathological Correlation
Discordance of clinical imaging and histopathology 
was observed in 12.5%, suggesting an inadequate sam-
pling of the suspicious lesion (Fig. 4). Not surprisingly, 
discordance was more frequent in CNB, which provides 
less biopsy material than VAB. However, the underesti-
mation rate of B3 lesions regarding the biopsy tech-
nique has rarely been investigated so far [23]. We ob-
served an upgrade rate of 42.9% in case of discordance, 
whereas in patients without discordance the upgrade 
rate after open surgery was 19.5%. This number also 
seems high at first glance [10–13], but one has to con-
sider that a notable number of patients (24.4%) of our 
study group received a further sampling with VAB after 
LN had been found in CNB, and open surgery was 
avoided in nearly all of these cases. Even more, one-
third of all patients underwent no further invasive diag-
nostics except for annual surveillance, a decision con-
firmed by an acceptable follow-up outcome as the inci-
dence of DCIS/invasive cancer was 7.1% during the 
follow-up period of 45 months (median). These results 
underline the benefit of re-evaluating clinical and path-
ological features in an interdisciplinary tumor board of 
a breast center [12, 14–17]. According to our knowl-
edge, our study is the first that considers the individual-
ized decision-making process regarding to the outcome 
of different treatment options in classical LN. The defi-
nition of radiological-pathological discordance de-
pends on the physician’s individual experience (Fig. 5). 
In 4 cases that were initially described as being discor-
dant, no open surgery or further sampling was per-
formed. In these cases, the tumor board-based review 
and discussion of clinical imaging and histopathology 
relativized “discordance.” All 4 patients have been dis-
ease-free in the follow-up, which indicates that unnec-
essary patient anxiety as well as costs and risks of open 
surgery were justifiably avoided.
Open surgery was clearly less frequently indicated af-
ter VAB than after CNB because VAB provides a more 
valid diagnosis due to a higher quantity of biopsy speci-
men, which was confirmed by a lower upgrade rate of 
these cases [23]. Our data are concordant to those of ear-
lier studies and emphasize the safety of the VAB tech-
nique [24]. However, the option of hand-held ultra-
sound-guided VAB in this context has hardly been re-
flected in the literature so far, but was considered in our 
study [8].
Fig. 5. Ultrasound lesion classified as BIRADS® 3 with LN in the 
biopsy specimen but missing a histological diagnosis that could 
explain a mass in clinical imaging. Subsequent surgery revealed an 
invasive lobular cancer. LN, lobular neoplasia.
Fig. 4. Discordance in clinical imaging and histopathological diag-
nosis. LN does not explain the architectural distortion on mam-
mogram (BI-RADS 5), even though ultrasound did not show a 
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The higher number of LN foci (≥3) in the biopsy spec-
imens was associated with a significantly higher number 
of upgrades in the surgical specimens (p = 0.01). In a re-
cent publication by Holbrook et al. [17], quantification 
of the terminal duct lobular units involved does not pre-
dict a higher upgrade rate. However, an increased num-
ber of foci can be a risk factor for coexisting invasive car-
cinoma or DCIS not present in the preoperative breast 
biopsies independently from the LN’s quantitative in-
volvement of terminal duct lobular units. Our data sug-
gest that in case of three or more histological foci of LN 
in a biopsy specimen, open surgery is indicated. Interest-
ingly, disease-free survival was decreased if LN was his-
tologically associated with calcification in our cohort. 
However, calcification-associated LN did not initially 
correlate with a higher upgrade rate. Therefore, the rec-
ommendation of open surgery in these cases might not 
be justified; instead, a close follow-up has to be empha-
sized. If microcalcifications in clinical imaging increase 
in the region of proofed LN, re-biopsy should be recom-
mended. As the event numbers in pure cohort are low, 
this result should be interpreted with caution. Further 
studies are warranted to clarify the prognostic role of his-
topathological microcalcification in LN.
ILC was revealed in most cases of upgrading histopa-
thology. However, NST and DCIS were present in 35.3% 
and 11.8%, respectively. In the current models of breast 
cancer pathogenesis, the development of ILC differs from 
NST [25]. On the other hand, coincidence of LN and 
DCIS is known, and a shift from NST towards ILC can be 
observed in mixed tumors [26]. It would be of great inter-
est to observe whether an upgrade into NST and DCIS has 
to be regarded as a coincidence, probably based on mech-
anisms of a “sick lobule,” or if a shift from LN to NST 
could also be plausible [27].
Follow-Up Outcome
LN has up to a four-fold increased risk of subsequent 
invasive breast cancer [13]. During a median follow-up 
of approximately 4 years, we observed occurrence of 
DCIS or invasive cancer in 11.9%, most of which was in 
the ipsilateral breast, but only 3.5% in the same quad-
rant. However, LN increases the risk of breast cancer in 
both breasts, and our results are in line with studies 
showing a higher rate of ipsilateral cancer in the follow-
up [28, 29]. Histologically microcalcification worsened 
the outcome, but our data showed no impact of initial 
clinical or radiological factors to the disease-free follow-
up. This is also the case for the upgrade-relevant factors 
of radiological-pathological discordance and pathologi-
cal number of foci in the initial biopsy specimen. Open 
surgery of classical LN did not improve the follow-up 
outcome.
Strengths and Weaknesses
For the time being, there are no guidelines for clinical 
practice in LN as the outcome results of numerous studies 
are contradictory [9–13]. The current expert-based con-
sent trends towards less invasive treatment, but not with-
out conflicts [8]. Our study is the first that considers the 
factors of diagnostic method, pathological factors, radio-
logical-pathological correlation, and decision-making 
process in a large number of patients. Our study includes 
a retrospective data analysis with several potential con-
founders. Although our study has a higher case number 
and longer follow-up, the variance of performed treat-
ments makes it less comparable to previous studies. How-
ever, this also reflects clinical practice as it is increasingly 
recommended. A careful histopathological review re-
vealed coexisting B3 lesions of other categories. Exclud-
ing these cases offers more precise data about LN. How-
ever, we did not subcategorize LN into atypical lobular 
hyperplasia and lobular carcinoma in situ like other au-
thors, though this is controversial in biopsy specimen.
Conclusion
LN of classical type is an incidental finding in most 
cases and is per se not an indication for further treatment. 
However, our results show that an increased number of 
LN foci in the preoperative breast biopsy showed a sig-
nificant association with upgrade in the consecutive sur-
gical excision, which should be considered in the interdis-
ciplinary preoperative board and be an integral part of the 
histopathology report. The association of classical LN 
with histological microcalcification correlates with de-
creased disease-free survival. An interdisciplinary deci-
sion-making process is crucial to avoid missing a cancer, 
especially in case of radiological-pathological discor-
dance. In case the initial diagnosis was set by CNB, sec-
ond-line VAB is a safe alternative to open surgery in most 
cases.
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